Ali Khan, MD
Internal Medicine · Buckhannon, WVNPI 1528089158
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,858 of the $21,410 with a category attached, or 78.7%. 43 manufacturers reported payments, led by Amgen at 31.8% of the total. Reporting peaked in 2024 at $7,432 and has fallen 69.6% since, to $2,257 in 2025. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,085 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- AstraZeneca$2K
- AbbVie$2K
- Boehringer Ingelheim$768
- Esperion Therapeutics, Inc.$728
- Sanofi-aventis U.S. LLC$689
- plus $8K from 37 others
What the payments were for
- Consulting fees$3,32516%
- Travel & lodging$1,0805%
- Food & beverage$16,85879%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,410 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 13 | $739,708 |
| MounjaroTirzepatide | 198 | $350,895 |
| JardianceEmpagliflozin | 81 | $110,405 |
| EliquisApixaban | 51 | $70,922 |
| FarxigaDapagliflozin Propanediol | 50 | $70,126 |
| XareltoRivaroxaban | 56 | $64,174 |
| TrulicityDulaglutide | 39 | $64,137 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $63,271 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $42,645 |
| JanuviaSitagliptin Phosphate | 32 | $38,634 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $28,450 |
| EntrestoSacubitril/Valsartan | 22 | $27,075 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $25,331 |
| LinzessLinaclotide | 16 | $15,624 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $15,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $6,813 | $739,70813 claims |
| Lilly USA, LLCMounjaro, Trulicity | $392 | $415,032237 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,475 | $115,704118 claims |
| Boehringer IngelheimJardiance | $768 | $110,40581 claims |
| PfizerEliquis | $627 | $70,92251 claims |
| Johnson & JohnsonXarelto | $515 | $64,17456 claims |
| GSKTrelegy Ellipta | $555 | $63,27160 claims |
| MerckJanuvia | $541 | $38,63432 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $689 | $28,45025 claims |
| NovartisEntresto | $369 | $27,07522 claims |
| AbbVieLinzess, Synthroid | $2,293 | $16,78328 claims |
| Esperion Therapeutics, Inc.Nexlizet | $728 | $15,30014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Buckhannon
- William ChapmanCharleston$1.7M
- David PickeringParkersburg$599K
- Govind PatelFairmont$59K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
- Joseph HashemBerkeley Springs$21K
- David PatickHuntington$18K
- Phillip TriplettCharleston$17K
- Atul ShettyWeirton$15K
- Roy BowdenCharleston$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.